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Summary 
Induction of a T-cell mediated antitumor response is the ultimate goal for tumor immunother- 
apy. We demonstrate here  that  antibody-targeted IL2 therapy is  effective against established 
pulmonary and hepatic melanoma metastases in a syngeneic murine tumor model. The effector 
mechanisms involved in this tumor eradication are not dependent on NK cells, since the thera- 
peutic effect of antibody-IL2 fusion protein was not altered in NK cell-deficient mice. In con- 
trast, T  cells are essential for the observed antitumor effect, since therapy with antibody-IL2 fu- 
sion proteins is  unable  to induce  tumor eradication  in  T  cell-deficient SCID mice.  In vivo 
depletion studies characterized the essential effector cell population further as CD8+  T  cells. 
Such CD8+ T  cells, isolated from tumor bearing mice after antibody-directed IL2 therapy, ex- 
erted a MHC class I-restricted cytotoxicity against the same tumor in vitro. These data demon- 
strate the ability of antibody-targeted IL2 delivery to induce a T  cell--dependent host immune 
response  that is  capable of eradicating established melanoma metastases in  clinically relevant 
organs. 
M 
ost  progressively  growing  neoplasms,  e.g.,  mela- 
noma, do not provoke antitumor immune responses 
that  are  capable  of controlling  the  growth  of malignant 
cells, in spite of the fact that these cells express tumor-asso- 
ciated,  T  cell epitopes. Ahnost two decades ago, Talmage 
et al.  (l)  first described a tumor cell line that failed to in- 
duce  an  allogeneic  T  cell  response  despite  its  apparently 
normal expression of MHC molecules.  Furthermore,  they 
demonstrated that this defective T  cell activation could be 
restored by cytokines  (1);  thereby providing the  rationale 
for cytokine based forms of immnnotherapy. 
A  therapeutic approach currently receiving much atten- 
tion is the  ex vivo genetic modification of tumor cells  to 
express  various  cytokines  (2,  3).  When  produced  by tu- 
mors, many of these cytokines induce a local inflammatory 
response which results in elimination of the injected tumor 
cells.  In some cases, systemic immune responses are gener- 
ated  against challenge  with  the  wild-type parental  tumor. 
Since most cytokines are paracrine factors working physio- 
logically at high concentrations within a few cell diameters 
from  their  cell  of origin,  this  gene  transfer approach,  in 
general can not be replaced by systemic cytokine adminis- 
tration unless the cytokine is directed preferentially to the 
tumor site (4). 
We recently demonstrated the feasibility of an alternative 
therapeutic  approach for cancer that  combines high local 
concentrations  of cytokines  in  the  tumor  microenviron- 
ment,  low  systemic  toxicities,  and  a  technically  simple 
modus operandi (5, 6). This goal was achieved by the con- 
struction  of fusion  proteins  consisting  of tumor-specific 
monoclonal antibodies  and cytokines; thereby,  employing 
the  unique  targeting  ability  of antibodies  to  direct  cyto- 
kines  to  the  tumor site.  Here,  we  demonstrate the  effec- 
tiveness  of antibody-targeted  IL2  therapy  for  established 
pulmonary and hepatic melanoma metastases in a syngeneic 
tumor model that enabled the  analysis  of effector mecha- 
nisms responsible for the  therapy-induced  tumor eradica- 
tion.  This analysis  revealed CDS+  T  cells  as the  essential 
effector population. 
Materials and Methods 
Cell Lines, Animals, and Reagents.  The  routine  melanoma  cell 
lines,  B16  and  B78-D14,  have been  described  previously  (7). 
B78-D14 was derived  from B16 melanoma cells by transfection 
with  genes  coding  for  f3-1,4-N-acetylgalactosaminyltransferase 
and ot-2,8-sialyltransferase inducing  a constitutive  expression  of 
the gangliosides GD2 and GD3. 
Mouse/human chimeric  antibodies  directed  against the EGF 
receptor (ch225) or GI)2 (chl4.18)  were constructed  by joining 
the cDNA for the variable region of the routine antibodies with 
the constant regions of the ",/1 heavy chain and the K light chain. 
The antibody-interleukin  2 fusion protein ch14.18-IL2  was con- 
structed by fusion of a synthetic sequence coding for human IL2 
to the  carboxyl end of the human C'y1 gene followed  by inser- 
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Volume 183  May 1996 2361-2366 tion into the eukaryotic expression  vector pdHL2. The resulting 
vector was introduced into Sp2/0-Ag14 cells, Each ~g of fusion 
protein corresponds to approximately  3,000 IU oflL-2 activity. (5). 
C57BL/6J, C57BL/6J bg/bg and C57BL/6J scid/scid mice were 
obtained  from Jackson  Laboratory at  the  age  of 4-6  wk  and 
housed under specific pathogen-free conditions. 
In Vivo Depletion with mAb.  Pat lgGz~ anti-UP4 (done H129.19) 
and rat IgG2a anti-CD8 (clone 53-6.7) mAb were used for in vivo 
depletion of T  cell subsets (8). Protocols yielding maximum de- 
pletion ofT cell subsets, i.e., over 95% as determined by indirect 
immunofluorescence staining and cytofluometric analysis of  lymph 
nodes and spleens, consisted of  weekly i.p. injections  of 500 p~g of 
the respective  mAb. 
Experimental Lung Metastases.  Single  cell  suspension  of 5  ￿ 
10  ~ tumor cells in 500  gtl PBS were injected into the lateral tail 
vein. After 7 d micrometastases were present disseminated through- 
out the lungs and were invading into the pulmonary alveoli. At d 
28 after tumor cell injection,  grossly visible metastases were present 
on the surface of the organ. 
Experimental Hepatic Metastases.  Tumor cells (2.5 X 106) were 
injected in  100 ILl RPMI 1640 with a 27-gauge needle beneath 
the splenic  capsule over a period of 60 s, followed by ligation of 
the splenic  pedicle  with a 4.0 silk suture and the removal of the 
spleen.  35  d after this procedure the animals were sacrificed and 
examined for metastases. 
Biodistribution.  The  ch14.18-IL2 fusion protein  was  labeled 
with 12sI as described  (6). Experimental  hepatic  or pulmonary me- 
tastases were induced as described above. 10 d after tumor cell in- 
oculation,  animals received  one i.v. injection  of 5 mCi 12SI-labeled 
ch14.18-IL2 fusion protein. Animals were killed  12 h after injec- 
tion. 
Statistical Analysis.  The  statistical  significance  of differential 
findings between experimental groups of animals was determined 
by student's  t test.  The  nonparametric Wilcoxon rank sum test 
was chosen when the data were not amenable for parametric tests 
as  defined  by the  David-Pearson-Stephen's test.  Findings  were 
regarded as significant if two-tailed P values were ~0.01. 
Results 
Therapeutic EfiTcacy of Antibody-IL2 Fusion Proteins.  We 
previously demonstrated  that  the  genetic  fusion of IL2 to 
the carboxy-terminal end of an antibody heavy chain changes 
neither the biological activity of IL-2 nor the binding affin- 
ity of the monoclonal antibody (5,  6).  To test the effect of 
these antibody-IL2 fusion proteins on melanoma metastases 
in vivo, we  employed a number of different experimental 
tumor models using B16 melanoma cells, which had been 
transfected  with  genes  coding  for  [~-l,4-N-acetylgalac- 
tosaminyltransferase  and  ot-2,8-sialyltransferase  resulting in 
a constitutive expression  of the gangliosides Gin,  the anti- 
gen  recognized  by  ch14.18-IL2.  These  tumor  cells  form 
experimental  pulmonary  and  hepatic  metastases  following 
intravenous  or intrasplenic  injection,  respectively.  After  1 
wk these  were present  as disseminated,  established  nficro- 
metastases. 
The first series of experiments addressed the effect of the 
antibody-IL2  fusion  protein  on  disseminated,  established 
puhnonary metastases. Treatment of mice 1 wk after tumor 
cell inoculation by i.v. administration of 8  Dg ch14.18-IL2 
fusion  protein  for  7  d  completely  eradicated  pulmonary 
micrometastases  in  14 of 16 animals  (Table  1).  This  com- 
plete eradication of micrometastases was confirmed by his- 
tologic  examination  of serial  sections  of lung  specimens 
(data not shown). For the remaining two animaIs the tumor 
load was dramatically reduced to one or two grossly visible 
pulmonary loci, as compared to control animals which suf- 
fered from more  than  500 pulmonary metastases,  after re- 
ceiving either no treatment or the combination of equimo- 
lar amounts of recombinant IL2 (24,000 I.U.) and ch14.18 
mAb  (8  txg).  Similar  results  were  obtained  when  animals 
bearing disseminated  hepatic metastases  established for 7  d 
were treated i.v. with 8  Ixg ch14.18-IL2 fusion protein for 
7  d  (Table  1).  This treatment  resulted in complete regres- 
sion  of micrometastases  in  87.5%  of these  animals.  The 
specificity  of the  antitumor  effect  of ch14.18-IL2  fusion 
proteins  was  established,  since  a fusion protein  that  is not 
reactive with the tumor cells completely failed to exert any 
antitumor  effects  (Table  1).  Differences  in  the  number  of 
metastatic  pulmonary loci  or the  hepatic  metastatic  score 
between  animals  receiving  the  specific fusion protein  and 
those subjected to other treatments were statistically signifi- 
cant (P ~<0.002). 
Although no metastatic  loci could be detected by mac- 
roscopic and/or histologic examination in the  animals fol- 
lowing treatment  with  ch14.18-IL2  these  mice  could still 
suffer from minimal  residual  disease.  Survival studies  were 
performed to measure the extent of such a hypothetical re- 
sidual disease. The mean survival time of mice after induc- 
tion of experimental pulmonary metastases without further 
treatment was 41 d. This survival time was not significantly 
altered by the administration  of ch14.18  antibody in com- 
bination  with  recombinant  IL2  (mean  =  44  d),  but  was 
more than doubled by treatment with the ch14.18-IL2 fu- 
sion  protein.  The  same  was  true  for mice  suffering from 
hepatic  metastases.  These  mice lived at least  twice  as long 
after therapy with ch14.18-IL2, than control animals (mean 
51  or 55  d,  respectively).  Only one of the  treated  animals 
died within the  observation period.  At the end of the  ob- 
servation  period  a  post  mortem  examination  revealed  no 
metastatic  disease in any of the major peripheral  organs or 
the central nervous system. 
Biodistribution ofchl4.18-IL2.  We  previously  demon- 
strated  that  fusion  proteins  localize  in  antigen-expressing 
subcutaneous tumors in nude nfice (6).  However, the clin- 
ically more relevant question is whether the fusion protein 
is able to target micrometastases in affected organs of a syn- 
geneic host. The biodistribution of ~25I-ch14.18-IL2 fusion 
protein in C57BL/tJ mice suffering from either hepatic  or 
pulmonary metastases,  10 d after experimental induction with 
B78-D14 melanoma cells,  is shown in Fig.  1. The amount 
of radioactivity in livers and lungs of these or naive animals 
was  determined  12  h  after  i.v.  injection  of I2SI-ch14.18- 
IL2. This analysis revealed  a strong localization of the  tu- 
mor specific  fusion  protein  within  the  tumor bearing  or- 
gans. Since only parts of the organs' tissue is involved in the 
metastatic process, the ratio of z2SI-ch14.18-IL2 fusion pro- 
tein localizing to the tumor or to normal tissue can be ex- 
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Pulmonary metastasis  Treatment*  No. of Foci 
Hepatic Metastasis 
None 
rIL2  +  ch14.18 
ch225-IL2 
chl4.18-IL2 
Treatment 
254,  >500, >500, >500, >500, >500, >500, >500'~ 
>500, >500, >500, >500, >500, >500, >500 
96, 167, 231,  >500, >500, >500, >500, >500 
82, 151, 154, 163, >500, >500, >500, >500 
113, 136, 200, >500, >500, >500, >500 
0, 0, 0, 0, 0, 0, 1, 2 
0, 0, 0, 0, 0, 0, 0, 0 
None  2, 3, 3, 3, 3, 3, 3~ 
rlL2 +  ch14.18  2, 2, 2, 3, 3, 3, 3, 3 
ch14.18-IL2  0, 0, 0, 0, 0, 0, 0, I 
Metastatic  Scorell 
*Experimental puhnonary and hepatic metastases were induced by i.v. injection of 5 ￿  10  6 or intrasplenic  injection of 2.5 ￿  10  6 B78-D14 cells, re- 
spectively. Treatment was started 1 wk thereafter and consisted  of daily i.v. administration  of PBS, 8 I~g chimeric monoclonal antibody ch14.18 and 
24000 IU recombinant IL2, or 8 nag of either the non-specific fusion protein ch225-lL2 or the tumor-specific fusion protein ch14.18-IL2 as indi- 
cated for seven consecutive days. 
*All experimental groups were started with eight mice; animals  found dead before the planned killing date were not included in the evaluation. 
SDifferences in numbers of metastatic foci and scores between  the  fusion protein  group and all control groups were statistically significant 
(P ~0.001). 
IIResults are given as metastatic score with 0 =  no visible metastatic loci, 1 = less than 5% of the liver surface covered with metastatic foci, 2 -- be- 
tween 5 and 50% of the liver surface covered with metastatic loci, and 3 = more than 50% of the liver surface covered with metastatic foci. 
pected to be even higher than the experimental results in- 
dicate. 
T  Cell Dependency  of Fusion  Protein-induced  Tumor Rejec- 
tion.  To test whether NK cells are essential for the antitu- 
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Biodismbution of ch14.18-IL2. C57BL/6 mice beating ei- 
ther no (white), pulmonary (striped), or hepatic (black) metastases estab- 
lished for 14 d were injected with 5 I.tCi t2SI-labeled  ch14.18-lL2 and the 
amount of radioactivity in lung or liver was measured 12 h thereafter. 
Each value represents the mean and standard deviation  for three animals. 
mor effect of antibody-IL2 fusion proteins, we induced ex- 
perimental  pulmonary  metastases  of  B78-D14  cells  in 
C57BL/6 beige~beige mice. Since these mice lack functional 
NK activity, any therapeutic host response induced is inde- 
pendent of NK cells. This was the case,  as treatment of tu- 
mor bearing NK-deficient mice with ch14.18-IL2 caused a 
complete eradication of tumor micrometastases (Table 2). 
The  second series  of studies  with  immunodeficient mice 
addressed  the relevance of T  cells for the  observed tumor 
eradication. B78-D14 cells were injected i.v. into T  cell- 
deficient C57BL/6 scid/scid mice and therapy with ch14.18- 
IL2 was started 7 d thereafter. In the absence of T  cells the 
therapeutic  efficacy of the  antibody-IL2 fusion protein is 
dramatically reduced. In fact, a complete eradication ofmi- 
crometastases was not achieved in any of the animals (Table 
2).  This observation strongly suggests  a  T  cell-dependent 
mechanism for  the  demonstrated  antitumor effect.  Thus, 
the  participation of T  cell  subsets  in the  fusion protein- 
induced tumor regression was  investigated by systemic in 
vivo depletion of T  cell subpopulations with specific anti- 
bodies. Since NK cells might be able to substitute for some 
functions of depleted T  cell populations, these studies were 
clone in C57BL/6 beige~beige mice. These studies revealed 
that depletion of CD4+  T  cells did not significantly inter- 
fere with the antibody-IL2 induced immune response (Ta- 
ble 2). In contrast, depletion of CD8 +  or both CD4 +  and 
CD8+  cells abrogates the therapeutic effect of the adminis- 
tered fusion protein. Provided that depletion of each T  cell 
subset was effective and specific, these results indicate that 
2363  Becker et al.  Brief  Definitive Report Table 2.  Effect of Antibody-IL2 Fusion Protein  Therapy on Micrometastases in Immunodeficient  and T  Cell-depleted Mice 
Mice*  In vivo depletion*  Treatment  No. of Foci 
C57BL/6 beige~beige 
C57BL/6 scid/scid 
C57BL/6 beige~beige 
None  None 
None  rlL2 +  ch14.18 
None  ch14.18-IL2 
None  None 
None  rlL2 +  ch14.18 
None  ch14.18-IL2 
None  None 
None  ch14.18-IL2 
CD4  ch14.18-IL2 
CD8  ch14.18-IL2 
CD4 +  CD8  ch14.18-IL2 
>500,  >500,  >500,  >500,  >500,  >500,  >500~ 
149,  187,  >500,  >500,  >500,  >500,  >500,  >500 
0, 0, 0, 0, 0, 0, 3, 21 
>500,  >500,  >500,  >500,  >500,  >500 
149,  187,  >500,  >500,  >500,  >500,  >500,  >500 
98,  131,  150,  171,  180,  180, 200,  >500 
>500,  >500,  >500,  >500 
0,0,0,  2 
0, 0, 22, 62 
56, 79,  126,  >500 
78, 142,  >500,  >500 
*Experimental pulmonary metastases were induced in C57BL/6 beige~beige or scid/scid mice by i.v. injection of 5  X  10  ~' B78-D14 cells; treatment 
was started  1 wk thereafter and consisted of daily i.v. administration  ofPBS, 8 p~g chimeric monoctonai antibody ch14.18  and 24,000  IU recombi- 
nant IL2 or 8 btg of the tumor-specific fusion protein ch 14. l 8-IL2 as indicated for 7 consecutive days. 
*C57BL/6 beige/beige mice were depleted of CD4+, CD8+  or both cell populations  by weekly i.p. injections of 500  b~g anti-CD4, anti-CD8 or 
both mAb starting 3 d before induction of tumors. 
~AI1 experimental groups were started with eight mice; animals found dead before the planned killing date were not included in the evaluation. 
only the presence of CD8+  T  cells is mandatory for tumor 
eradication. 
The third line of evidence indicating the involvement of 
CD8+  T  cells was provided by cytotoxicity studies.  Spleen 
cells isolated from mice after induction  of pulmonary  me- 
tastases  and  subsequent  treatment  with  ch14.18-IL2  dis- 
played a  high  cytolytic  activity against  B78-D14  cells in  a 
4-h 5*Cr-release assay (Fig. 2 A). Enrichment for CD8+  T 
cells,  demonstrated  that  this  cell  population  provides  the 
major contribution to the detected cytolytic activity (Fig. 2 
B).  Furthermore, blocking studies with  antibodies  against 
H-2Kb/H-2D b  antigens  (clone  28-8-6,  C3H  lgG2~,  K) 
proved  that  the  killing  of B78-DI4  cells  by  either  unse- 
lected primed lymphocytes  or the  CD8+  subset  thereof is 
MHC  class I restricted.  In contrast,  spleen cells from tumor 
bearing mice treated with the same amount of a fusion pro- 
tein  (ch225-IL2)  not  reacting  with  the  tumor  showed  no 
specific lysis of tumor cells. 
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Figure 2.  T  cell mediated  cy- 
totoxicity  against B78-D14  in- 
duced  by  antibody-IL2  fusion 
proteins.  C57BL/6 mice bearing 
pulmonary  metastases  of  B78- 
D14  melanoma  cells,  were 
treated  1 wk after tumor induc- 
tion  with  fl  p.g  ch14.18-IL2 
(squares)  or  nonspecific  fusion 
protein  ch225-1L2  (circles) for 
7 d.  Splenocytes  (A)  or  CD8+ 
cells (/3) were isolated  3  d  after 
cessation of therapy and analyzed 
for  their  lytic  activity  against 
B78-Dt4  cells.  Experiments 
were  performed  in  the  absence 
(open symbols) or presence  (closed 
symbols) of an excess (5(} vg/ml) 
of  antibodies  directed  against 
H-2Kb/H-2D  b MHC class 1 an- 
tigens (clone 28-8-6,  C3H lgG2~, 
K). Percentage  of specific lysis is 
plotted  on the y-axis for various 
effector  to  target  rations.  Each 
value  represents  the  mean  and 
standard deviation  for three  ani- 
nlals. 
2364  Eradication of Metastatic Melanoma Discussion 
Antibody-cytokine  fusion proteins  combine  the  unique 
targeting ability of antibodies  with the  multifunctional  ac- 
tivity  of cytokines.  In  the  present  report  we  demonstrate 
the  therapeutic  effectiveness  of  such  constructs  for  the 
treatment  of established hepatic  and pulmonary melanoma 
metastases.  Several lines of evidence, i.e., in vivo depletion 
studies and in vitro cytotoxicity assays, indicate that this an- 
titumor effect is largely dependent on CD8+  T  cells, which 
kill the tumor cells in an MHC  class I-restricted manner. 
Since  becoming available in recombinant  form,  IL2 has 
been  used  as an in vivo T  cell growth factor in the  treat- 
ment  of patients  with  advanced  renal  cell  carcinoma  or 
melanoma (4). The aim of this partially successful approach 
is  to  generate  or  propagate  tumor-reactive  lymphocytes. 
Forni  et al.  demonstrated  that injection  of a  physiological 
dose of IL2 directly into tumors caused suppression of their 
growth (9). The major advantage of an in situ apphcation is 
that it  avoids  certain  forms of toxicity associated with  the 
systemic use of cytokines.  Recendy,  in situ  cytokine ther- 
apy  has  been  developed  further  by  transferring  cytokine 
genes into tumor cells (2, 3). We reasoned that by using the 
targeting  ability  of tumor-specific  monoclonal  antibodies 
we  could  develop  a  technically  more  simple  strategy  to 
achieve  effective  concentrations  of IL2 in  the  tumor  mi- 
croenvironment  (5).  We  demonstrate  here  that  this  ap- 
proach is capable to induce and maintain effective IL2 con- 
centrations at the tumor site. Analysis of the biodistribution 
of 125I-ch14.18-IL2  demonstrated  its localization  in  tumor 
bearing  livers  and  lungs.  Therefore,  it  seems  feasible  to 
achieve effective local cytokine concentrations at the tumor 
site in a non personalized way, which makes this approach 
more practicable  for clinical  apphcations  than  the  ex vivo 
transfer of cytokine genes.  Furthermore,  antibody-targeted 
IL2 therapy is essentially  different from such  gene  transfer 
approaches  with  regard  to  the  order  of events;  the  latter 
aims at the induction of an antitumor host immune response 
by  re-inoculation  of IL2-producing  tumor  cells,  whereas 
antibody-IL2 fusion protein  therapy direct  IL2 to the  mi- 
croenvironment  of established  tumors.  This  is particularly 
noteworthy,  not only because of the high clinical relevance 
of this setting, but also because it might change immune re- 
actions in several ways. The host immune system has most 
likely encountered  the tumor before the immune modula- 
tion is initiated.  Therefore, priming of T  cells may have al- 
ready  occurred  via  antigen  presenting  cells,  e.g.,  macro- 
phages  or  dendritic  cells;  especially,  since  tumor  cells  are 
more sensitive to the innate  cytodestructive effects of these 
cells immediately after inoculation  than after establishment 
in micrometastases.  Another possibility is that some tumor 
cells might  have metastasized  to  the  draining  lymph node 
during this period.  This would overcome the problem that 
naive T  cells are compartmentalized in blood and lymphoid 
organs (10). 
Taking  these  considerations  into  account,  there  are  a 
number of possible mechanisms by which antibody-IL2 fu- 
sion proteins can induce eradication  of disseminated tumor 
metastases.  First,  the  tumor cells themselves might interact 
with naive T  cells with IL-2 acting as the second costimu- 
latory signal in the activation of cytotoxic T  cells. A  recent 
model proposed by J.  Sprent for the  activation of naive T 
cells provides  the  rationale  for this  mechanism  (11)  .  Ac- 
cording  to  this  model,  high-avidity  interactions  between 
peptide-MHC  class  I  complexes  and  the  T  cell  receptor 
promotes strong cross-linking of T  cell receptor-CD3  com- 
plexes,  which  in  turn  leads  to  strong  signaling;  thereby 
stimulating  the  production  of cytokines,  such  as  IL2,  and 
receptors  thereo~  costimulation  boosts  the  T  cell receptor 
mediated signal.  If the intensity of signaling is below a cer- 
tain  threshold,  e.g.,  when  the  density  of peptide-MHC 
complexes  or  the  level  of costimulation  is  low,  the  re- 
sponding T  cells express IL2 receptors, but no IL2. Hence, 
these T  cells fail to proliferate unless exposed to exogenous 
IL2. The second possible scheme for the estabhshment ofT 
cell activation is based on  tumor antigens  being processed 
by antigen-presenting  cells that transfer to the lymph node, 
where  T  cell priming then occurs.  It has been shown that 
preactivated macrophages,  dendritic  cells and  granulocytes 
express receptors for tL2 and that in vitro culture with tL2 
causes functional changes in these cells (12,  13). After arriv- 
ing at the tumor site these cells may be activated by the an- 
tibody-targeted  IL2  to  kill  these  tumor  cells  and  subse- 
quently present the tumor antigens to T  cells. One further 
possibility is that the CD8+  T  cells act as non-specific IL2- 
activated killer  cells.  However,  since  the  apphed  amounts 
of IL2-activity  are  too  low  to  induce  a  generahzed  LAK 
cell phenomenon  (4), and apphcation of a tumor-unspecific 
fusion  protein  failed  to  show  any  therapeutic  effect or  to 
induce B78-D14 cytolytic cells, this possibility is rather un- 
likely. Furthermore,  in vitro cytotoxicity studies confirmed 
the MHC  class I restriction of the antibody-IL2 fusion pro- 
tein-induced  immune response. 
In conclusion,  we have demonstrated the efficacy of an- 
tibody targeted-IL2 in the treatment of estabhshed, dissem- 
inated melanoma metastases affecting clinically relevant or- 
gans.  The fusion protein-induced  eradication  of the tumor 
is critically dependent  on T  cells, and is likely due to either 
priming of naive T  cells, the activation ofcytotoxic effector 
cells, or both. 
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